Forge Biologics Receives Priority Medicines (PRIME) Designation from the European Medicines Agency (EMA) for Novel Gene Therapy FBX-101 for the Treatment of Patients with Krabbe Disease Read more
Amylyx Pharmaceuticals Announces Exclusive AMX0035 Distribution Agreement with Israel-Based Neopharm Read more
AffaMed Therapeutics to commercialize Galcanezumab for Migraine Prevention in Mainland China Read more
Orphagen Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for OR-449 for the Treatment of Pediatric Adrenocortical Carcinoma Read more
CARsgen Therapeutics and Huadong Medicine Announce Collaboration Agreement For Zevorcabtagene Autoleucel In Mainland China Read more
Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above Read more